• Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 561.76%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.36
▲ +0.02 (1.49%)

This chart shows the closing price for PGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Precigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PGEN

Analyst Price Target is $9.00
▲ +561.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $9.00, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 561.76% upside from the last price of $1.36.

This chart shows the closing price for PGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Precigen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Cantor FitzgeraldReiterated RatingOverweightLow
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$7.00Low
3/22/2024JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
3/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$14.00Low
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
5/23/2023JPMorgan Chase & Co.Initiated CoverageNeutralLow
3/7/2023HC WainwrightReiterated RatingBuy$6.00Low
3/7/2023JMP SecuritiesReiterated RatingBuy$14.00Low
1/30/2023Cantor FitzgeraldBoost TargetOverweight$7.00 ➝ $10.00Low
11/18/2022Cantor FitzgeraldInitiated CoverageOverweight$7.00Low
11/10/2022JMP SecuritiesBoost TargetMarket Outperform$13.00 ➝ $14.00Low
8/9/2022HC WainwrightLower TargetBuy$10.00 ➝ $6.00Low
5/16/2022HC WainwrightReiterated RatingBuy$10.00Low
12/14/2021JMP SecuritiesReiterated RatingBuy$13.00Low
11/5/2021JMP SecuritiesReiterated RatingBuy$13.00Low
10/1/2021JMP SecuritiesReiterated RatingBuy$13.00Medium
8/10/2021HC WainwrightReiterated RatingBuy$10.00Low
5/11/2021HC WainwrightReiterated RatingBuyHigh
3/2/2021B. RileyBoost TargetBuy$10.00 ➝ $14.00High
2/25/2021Stifel NicolausInitiated CoverageBuy$13.00High
2/22/2021Wells Fargo & CompanyInitiated CoverageOverweight$14.00High
2/17/2021B. RileyInitiated CoverageBuy$10.00Medium
12/16/2020HC WainwrightBoost TargetBuy$8.00 ➝ $10.00High
6/24/2020HC WainwrightReiterated RatingBuy$8.00Low
6/10/2020JMP SecuritiesReiterated RatingOutperform$13.00High
5/8/2020HC WainwrightInitiated CoverageBuy$5.00Medium
8/12/2019Northland SecuritiesReiterated RatingHold$10.00Medium
8/9/2019Bank of AmericaLower TargetUnderperform$7.00 ➝ $6.00N/A
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 4 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/25/2024

Current Sentiment

  • 4 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Precigen logo
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $1.36
Low: $1.34
High: $1.37

50 Day Range

MA: $1.39
Low: $1.27
High: $1.53

52 Week Range

Now: $1.36
Low: $0.84
High: $1.88

Volume

422,809 shs

Average Volume

680,946 shs

Market Capitalization

$343.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Precigen?

The following sell-side analysts have issued research reports on Precigen in the last year: Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for PGEN.

What is the current price target for Precigen?

3 Wall Street analysts have set twelve-month price targets for Precigen in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 561.8%. JMP Securities has the highest price target set, predicting PGEN will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Precigen in the next year.
View the latest price targets for PGEN.

What is the current consensus analyst rating for Precigen?

Precigen currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PGEN.

What other companies compete with Precigen?

How do I contact Precigen's investor relations team?

Precigen's physical mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company's listed phone number is (301) 556-9900 and its investor relations email address is [email protected]. The official website for Precigen is www.precigen.com. Learn More about contacing Precigen investor relations.